Diversity and Disruption in Clinical Research


Capital infusion, Nasdaq debut ignite ‘agile’ approach to attracting patients without bounds

David Coman, CEO of Science 37, a decentralized clinical trials platform company, discusses his organization’s recent public debut via the SPAC route, how that’s powering its mission to enable universal and diverse access to clinical research, and the potential of “agile clinical trial” designs in disrupting the future drug development landscape for the better.

The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.